Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved (Q34153221)

31 July 2017

1 reference

title

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved (English)

1 reference

31 July 2017

0 references

1

Ralf Gold

1 reference

31 July 2017

publication date

1 January 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

25

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

37-52

1 reference

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11539820-000000000-00000

Whole brain volume changes in patients with progressive MS treated with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539820-000000000-00000

FTY720: mechanism of action and potential benefit in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539820-000000000-00000

FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539820-000000000-00000

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539820-000000000-00000

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539820-000000000-00000

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539820-000000000-00000

21 January 2018

1 reference

12 December 2020

The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration

1 reference

12 December 2020

Suppression of experimental autoimmune neuritis by leflunomide

1 reference

12 December 2020

The effect of cladribine on T(1) 'black hole' changes in progressive MS.

1 reference

12 December 2020

Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing

1 reference

12 December 2020

Factors that influence adherence with disease-modifying therapy in MS.

1 reference

12 December 2020

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

12 December 2020

Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis

1 reference

12 December 2020

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

12 December 2020

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

1 reference

12 December 2020

The future of multiple sclerosis therapy

1 reference

12 December 2020

A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events

1 reference

12 December 2020

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

12 December 2020

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

1 reference

12 December 2020

Identification and development of new therapeutics for multiple sclerosis

1 reference

12 December 2020

Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo.

1 reference

12 December 2020

Cladribine for multiple sclerosis: review and current status

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Antioxidants in multiple sclerosis: do they have a role in therapy?

1 reference

12 December 2020

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

1 reference

12 December 2020

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

1 reference

12 December 2020

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

1 reference

12 December 2020

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

1 reference

12 December 2020

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

12 December 2020

The Will Rogers phenomenon: the effect of different diagnostic criteria

1 reference

12 December 2020

Cladribine (2-chlorodeoxyadenosine)

1 reference

12 December 2020

Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis

1 reference

12 December 2020

The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

1 reference

12 December 2020

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion

1 reference

12 December 2020

Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation

1 reference

12 December 2020

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.

1 reference

12 December 2020

Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress

1 reference

12 December 2020

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

1 reference

12 December 2020

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

12 December 2020

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

12 December 2020

New oral drugs for multiple sclerosis

1 reference

12 December 2020

Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease

1 reference

12 December 2020

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

1 reference

12 December 2020

Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging

1 reference

12 December 2020

Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis.

1 reference

12 December 2020

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

1 reference

12 December 2020

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

1 reference

12 December 2020

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

12 December 2020

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

1 reference

12 December 2020

Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults

1 reference

12 December 2020

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

12 December 2020

Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice

1 reference

12 December 2020

The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation

1 reference

12 December 2020

10.2165/11539820-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1014461018

0 references

1 reference